The US FDA approval of Vizz was based on results from three randomised, double-masked, controlled Phase 3 studies.

Vizz being approved by the FDA marks a step in the right direction for treating vision loss in an accessible way.

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

Lenz Therapeutics has received approval from the Food and Drug Administration for Vizz (aceclidine ophthalmic solution) 1.44% ...

The US Food and Drug Administration has approved the first eye drop that can fix near vision, promising to help ...

The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...

The Food and Drug Administration has approved Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults.

It is anticipated that Vizz, manufactured by Lenz Therapeutics, will become commercially available in the US by the end of ...